Abstract
Adjuvant therapies, including chemotherapy [...]
Highlights
Adjuvant therapies, including chemotherapy, are a major reason for the improved survival in early breast cancer in North America and Europe
Comorbidities were present in 12 patients (4 diabetes mellitus, 2 pulmonary embolism, 3 prior chemotherapy, and 1 each Crohn disease, sleep apnea, and delayed wound healing), and 11 patients had received primary prophylaxis with filgrastim or pegylated filgrastim
Based on these limited observations, it appears that tc chemotherapy is associated with a higher fn rate than has been published or reported
Summary
Adjuvant therapies, including chemotherapy, are a major reason for the improved survival in early breast cancer in North America and Europe. As treatments have become more successful, the indications have expanded to include cancers in node-negative and in older women 1,2. Recent clinical trials have largely supported the additional benefit of taxane therapy, including benefit in older patients 3. The increase in the proportion of women treated and the improved survival mean that toxicities become increasingly important. A newer report has demonstrated the benefit for disease-free and overall survival of 4 cycles of docetaxel–cyclophosphamide (tc) chemotherapy over doxorubicin–cyclophosphamide chemotherapy and has reported acceptable toxicity with a fn rate of 5% 4. The tc regimen has become very popular in Ontario, in older age groups who are at increased risk of cardiotoxicity with anthracyclines, or in those eligible for trastuzumab 5
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
